Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype

V Grossmann, E Tiacci, AB Holmes… - Blood, The Journal …, 2011 - ashpublications.org
V Grossmann, E Tiacci, AB Holmes, A Kohlmann, MP Martelli, W Kern, A Spanhol-Rosseto…
Blood, The Journal of the American Society of Hematology, 2011ashpublications.org
Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1
and CEBPA mutations define World Health Organization 2008 provisional entities
accounting for approximately 60% of patients, but the remaining 40% are molecularly poorly
characterized. Using whole-exome sequencing of one CN-AML patient lacking mutations in
NPM1, CEBPA, FLT3-ITD, IDH1, and MLL-PTD, we newly identified a clonal somatic
mutation in BCOR (BCL6 corepressor), a gene located on chromosome Xp11. 4. Further …
Abstract
Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1 and CEBPA mutations define World Health Organization 2008 provisional entities accounting for approximately 60% of patients, but the remaining 40% are molecularly poorly characterized. Using whole-exome sequencing of one CN-AML patient lacking mutations in NPM1, CEBPA, FLT3-ITD, IDH1, and MLL-PTD, we newly identified a clonal somatic mutation in BCOR (BCL6 corepressor), a gene located on chromosome Xp11.4. Further analyses of 553 AML patients showed that BCOR mutations occurred in 3.8% of unselected CN-AML patients and represented a substantial fraction (17.1%) of CN-AML patients showing the same genotype as the AML index patient subjected to whole-exome sequencing. BCOR somatic mutations were: (1) disruptive events similar to the germline BCOR mutations causing the oculo-facio-cardio-dental genetic syndrome; (2) associated with decreased BCOR mRNA levels, absence of full-length BCOR, and absent or low expression of a truncated BCOR protein; (3) virtually mutually exclusive with NPM1 mutations; and (4) frequently associated with DNMT3A mutations, suggesting cooperativity among these genetic alterations. Finally, BCOR mutations tended to be associated with an inferior outcome in a cohort of 422 CN-AML patients (25.6% vs 56.7% overall survival at 2 years; P = .032). Our results for the first time implicate BCOR in CN-AML pathogenesis.
ashpublications.org